Overview

Pregabalin Epilepsy Add-On Trial

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin